Aequus Pharmaceuticals Management

Management criteria checks 4/4

Aequus Pharmaceuticals' CEO is Doug Janzen, appointed in Jan 2013, has a tenure of 11.33 years. total yearly compensation is CA$206.25K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 9.46% of the company’s shares, worth CA$188.31K. The average tenure of the management team and the board of directors is 7.8 years and 5.5 years respectively.

Key information

Doug Janzen

Chief executive officer

CA$206.3k

Total compensation

CEO salary percentage	100.0%
CEO tenure	11.3yrs
CEO ownership	9.5%
Management average tenure	7.8yrs
Board average tenure	5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Doug Janzen's remuneration changed compared to Aequus Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CA$3m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$3m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	CA$206k	CA$206k	-CA$3m
Sep 30 2022	n/a	n/a	-CA$3m
Jun 30 2022	n/a	n/a	-CA$2m
Mar 31 2022	n/a	n/a	-CA$2m
Dec 31 2021	CA$225k	CA$225k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$1m
Dec 31 2020	CA$212k	CA$212k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$2m
Jun 30 2020	n/a	n/a	-CA$2m
Mar 31 2020	n/a	n/a	-CA$3m
Dec 31 2019	CA$191k	CA$191k	-CA$3m
Sep 30 2019	n/a	n/a	-CA$3m
Jun 30 2019	n/a	n/a	-CA$3m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	CA$180k	CA$180k	-CA$3m
Sep 30 2018	n/a	n/a	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$4m
Dec 31 2017	CA$258k	CA$210k	-CA$4m

Compensation vs Market: Doug's total compensation ($USD149.89K) is about average for companies of similar size in the Canadian market ($USD174.31K).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.

CEO

Doug Janzen (54 yo)

11.3yrs

Tenure

CA$206,250

Compensation

Mr. Douglas Glen Janzen, also known as Doug, is Director of Elevate Farms Inc. from September 2022. Mr. Janzen has experience in banking investments and managing growth companies with a particular focus on...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Douglas Janzen	Chairman	11.3yrs	CA$206.25k	9.46% CA$ 188.3k
Ann Fehr	CFO & Corporate Secretary	7.8yrs	CA$136.13k	0.28% CA$ 5.5k
Grant Larsen	Chief Commercial Officer	3.8yrs	CA$244.58k	no data

7.8yrs

Average Tenure

Experienced Management: AQS's management team is seasoned and experienced (7.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Douglas Janzen	Chairman	11.3yrs	CA$206.25k	9.46% CA$ 188.3k
Marc Lustig	Independent Director	3.3yrs	no data	5.21% CA$ 103.7k
Christopher Clark	Director	9.4yrs	no data	no data
Iqbal Ahmed	Chairman of Strategic Advisory Board	5.5yrs	no data	no data
Anne Stevens	Director	9.4yrs	no data	no data
Rosa Braga-Mele	Member of Strategic Advisory Board	5.5yrs	no data	no data
Vikram Lekhi	Member of Strategic Advisory Board	5.5yrs	no data	no data
Ken Patterson	Member of Strategic Advisory Board	5.5yrs	no data	no data

5.5yrs

Average Tenure

50yo

Average Age

Experienced Board: AQS's board of directors are considered experienced (5.5 years average tenure).

Aequus Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

High number of new directors

Recent updates

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Health Check: How Prudently Does Aequus Pharmaceuticals (CVE:AQS) Use Debt?

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Is Aequus Pharmaceuticals (CVE:AQS) Using Debt Sensibly?

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Chairman & CEO recently bought CA$73k worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Chairman recently bought CA$58k worth of stock

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Chairman exercised options to buy CA$328k worth of stock.

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

New 90-day high: CA$0.28

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

New 90-day high: CA$0.23

Is Aequus Pharmaceuticals (CVE:AQS) Using Too Much Debt?

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age